Oligosaccharide-specific Induction of Interleukin 10 Production by B220+ Cells from Schistosome-infected Mice: a Mechanism for Regulation of CD4+ T-cell Subsets
Overview
Authors
Affiliations
Defining the factors and/or mechanisms that lead to the predominance of a particular CD4+ T-cell subset (Th-1 vs. Th-2) is an area of intense investigation. In murine schistosomiasis, Th-2-type T cells become predominant after deposition of eggs. The most immunoreactive egg components are glycoproteins. Previously we identified two interesting oligosaccharides found on schistosome eggs and schistosomula. One, lacto-N-fucopentaose III (LNFP-III) contains the interesting trisaccharide Lewisx, which is a weak ligand for P-selectin and is a sugar also found on the alpha and beta chains of the integrin lymphocyte function-associated molecule 1, a ligand for intercellular adhesion molecule 1. Because of the correlation between schistosome egg glycoproteins and Th-2 dominance, the present study examined whether LNFP-III and structurally related oligosaccharides were lymphostimulatory and/or able to induce factors known to down-regulate Th-1 cells. We found that LNFP-III and related sugars did induce proliferation of splenic non-T cells, B220+,CD4-,CD8- cells (B cells) of schistosome-infected and naive mice. In contrast to proliferation, LNFP-III was the only oligosaccharide that induced spleen cells to produce large amounts of interleukin 10 and prostaglandin E2, two molecules known to down-regulate Th-1 cells. Further, only spleen cells from infected mice produced cytokines after oligosaccharide stimulation. Interestingly, LNFP-III stimulation did not induce production of interleukin 4. Thus, a specific carbohydrate ligand has been identified that stimulates B cells to proliferate and produce factors that down-regulate Th-1 T cells. Further, we suggest that identical or structurally related ligands may contribute to the known Th-1 down-regulation in other parasitic diseases and in chronic blood-vascular diseases such as human immunodeficiency virus infection and a number of metastatic carcinomas and that this effect may, therefore, be a general phenomenon.
Chaye M, Gasan T, Ozir-Fazalalikhan A, Scheenstra M, Zawistowska-Deniziak A, van Hengel O PLoS Negl Trop Dis. 2023; 17(6):e0011344.
PMID: 37363916 PMC: 10328244. DOI: 10.1371/journal.pntd.0011344.
Human Milk Oligosaccharides: Potential Applications in COVID-19.
Chutipongtanate S, Morrow A, Newburg D Biomedicines. 2022; 10(2).
PMID: 35203555 PMC: 8961778. DOI: 10.3390/biomedicines10020346.
Biology of human milk oligosaccharides: From basic science to clinical evidence.
Sprenger N, Tytgat H, Binia A, Austin S, Singhal A J Hum Nutr Diet. 2022; 35(2):280-299.
PMID: 35040200 PMC: 9304252. DOI: 10.1111/jhn.12990.
Acharya S, Dadara A, Skelly P PLoS Pathog. 2021; 17(12):e1010064.
PMID: 34969052 PMC: 8718004. DOI: 10.1371/journal.ppat.1010064.
Human Milk Oligosaccharides: Their Effects on the Host and Their Potential as Therapeutic Agents.
Rousseaux A, Brosseau C, Le Gall S, Piloquet H, Barbarot S, Bodinier M Front Immunol. 2021; 12:680911.
PMID: 34108974 PMC: 8180913. DOI: 10.3389/fimmu.2021.680911.